Research Reports

Key takeaways

Net income was -$219.6M, deteriorating 575.9% year-over-year primarily from the decrease in other income (expense) caused by changes in warrant liability fair value linked to common stock price movements.

Diluted EPS was $-5.11, down 1865.4% year-over-year reflecting the substantial net loss expansion from warrant liability valuation changes.

Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital needs into early 2029 per current operating plan.

Full analysis

Vor Biopharma Inc. reported a significantly wider net loss of -$219.6M in Q1 FY2026 compared to -$32.5M in the prior year period, with diluted EPS falling to $-5.11 from $-0.26. This sharp deterioration stems primarily from the decrease in other income (expense), driven by changes in the fair value of warrant liabilities resulting from fluctuations in the quoted price of the Company’s common stock underlying the warrants. Such non-cash volatility underscores the impact of equity-linked instruments on the P&L, amplifying losses despite more modest underlying operational shifts.

VOR · Vor Biopharma Inc.

Summary

Key takeaways

Full analysis